SI-BONE (SIBN) Earnings Date & Reports

Key Takeaways

• Worldwide revenue reached $55.7 million in the third quarter of 2026, up 14.5% year over year from $48.7 million.
• Net loss narrowed to $3.6 million, or $0.08 per diluted share, beating the consensus estimate of a $0.13 per share loss.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) improved to $3.0 million from $2.3 million a year earlier.
• SI-BONE reaffirmed its full-year 2026 revenue guidance of $231 million to $233 million while lowering its operating expense growth outlook to 10.5%.
• Active U.S. physicians grew 16% year over year to roughly 1,770, and the alpha launch of iFuse Granite Onyx began expanding the company's addressable market.
• For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• To discover AI-driven trading strategies, explore Trending AI Robots.

Earnings Context and Why It Matters

SI-BONE, a developer of procedural solutions for compromised bone, delivered its third-quarter 2026 results as the company pushes into new clinical adjacencies beyond its core sacroiliac joint franchise. Investors are watching whether the recent FDA (Food and Drug Administration) clearance of iFuse Granite Onyx and favorable reimbursement changes can accelerate procedure volumes and broaden the company's total addressable market. The quarter also tests SI-BONE's path toward sustainable profitability, as improving operating leverage and disciplined expense management remain central to the investment thesis in a competitive medtech landscape.

Reported Results

SI-BONE reported worldwide revenue of $55.7 million for the third quarter of 2026, a 14.5% increase from $48.7 million in the prior-year period and slightly above the consensus estimate of about $55.3 million. U.S. revenue grew 13.9% to $52.8 million, driven by a 19.5% rise in procedure volume, partially offset by lower average selling price tied to procedure mix and growing adoption of the INTRA platform in office-based and ambulatory surgery center (ASC) settings. International revenue rose 27.0% to $2.9 million.

The company's net loss improved 20.7% to $3.6 million, or $0.08 per diluted share, compared with a net loss of $4.6 million, or $0.11 per share, a year earlier. Gross margin was 79.3%, slightly below the prior-year 79.8%, reflecting procedure and site-of-care mix. Operating expenses increased 9.7% to $48.5 million, while adjusted EBITDA climbed to $3.0 million from $2.3 million. Cash and equivalents stood at $146.3 million at quarter end.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like SI-BONE, it offers a structured way to surface actionable setups across sectors.

Market Reaction and Investor Sentiment

Shares of SI-BONE have been supported by improving fundamentals heading into the report, with the stock up roughly 11% over the prior three months and about 35% over the prior twelve months. The third-quarter beat on both revenue and earnings per share, combined with reaffirmed full-year guidance, reinforced the view that the company's procedure-driven growth remains intact. The market also appeared focused on the early traction of the iFuse Granite Onyx alpha launch, which management framed as a meaningful expansion of its addressable market, and on the October 1, 2026 diagnosis-related group (DRG) reimbursement changes that could lift procedure economics.

Forward Outlook and Key Factors to Monitor

SI-BONE reaffirmed its full-year 2026 revenue guidance of $231 million to $233 million, implying roughly 15% to 16% growth, and maintained its gross margin expectation of approximately 79.0%. Management also reduced its operating expense growth outlook to 10.5% from 12.0%, reflecting disciplined spending and operating leverage.

Looking ahead, investors should monitor the commercial ramp of iFuse Granite Onyx, which management says expands the estimated total addressable market (TAM) to roughly $5 billion. The company has also filed for a New Technology Add-on Payment (NTAP), which, if approved by CMS (the Centers for Medicare & Medicaid Services), would take effect in October 2027.

Other factors to watch include the pace of physician adoption across the INTRA and TORQ platforms, the impact of proposed reimbursement increases for hospital outpatient and ASC settings, and the company's progress toward its target of nearly 100 sales territories exiting 2026. Cost discipline, gross margin stability, and continued positive adjusted EBITDA will remain key markers of SI-BONE's path toward profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations